Director, National Accounts, West

Amylyx has an audacious mission to usher in a new era for treating diseases with high unmet needs. Where others see challenges, we see opportunities that we pursue with urgency, rigorous science, and unwavering commitment to the communities we serve. We are a clinical-stage company currently focused on post-bariatric hypoglycemia (PBH), Wolfram syndrome, and amyotrophic lateral sclerosis (ALS). Our mission is powered by our people.

Our core values – be audacious, be curious, be authentic, be engaged, and be accountable – creating a culture of caring. Amylyx has assembled an experienced team ready to take action because the communities we serve have no time to wait. If you share our passion and are determined to tackle some of medicine’s toughest problems, we encourage you to read the opportunity below and apply.

The Director of National Accounts (DNA) will serve as Amylyx’s primary interface with U.S. payers, supporting appropriate coverage and patient access planning in preparation for a potential future commercial launch of our lead product candidate.

This individual contributor role is responsible for developing and executing Amylyx’s national and regional payer engagement strategies to support evidence-based coverage discussions and patient access planning. This role serves as the primary interface with national and regional payers, PBMs, Medicare, Medicaid, and other government customers, while also partnering cross-functionally with Market Access Field Teams, HEOR, Medical Affairs, Patient Services, Sales, and Distribution teams in accordance with company policies and applicable laws and regulations.

We anticipate the start date of the Director National Accounts to be in September 2026.

Multiple Director of National Account positions may be filled and will be assigned to accounts based on business needs, customer alignment, and candidate experience and may evolve over time. While account assignments may change as the organization grows, current planning includes alignment to three broad territories. This role is currently planned to cover AK, HI, WA, OR, , MT, WY, ND, SD, MN, NE, CA, NV, UT, CO, AZ, NM, TX:

• United Health Group  – UHC/Optum Rx/Emisar
• Kaiser Permanente
• Assigned national and regional payer accounts
• Assigned State Medicaid Fee-for-Service Programs
• Assigned VA/DoD/TRICARE responsibilities

• Develop and execute national and regional payer strategy across commercial, Medicare Part D/MA-PD, Managed Medicaid, FFS Medicaid, VA/Tricare/DoD, and PBMs to support appropriate coverage and access objectives.
• Anticipate payer evidence needs; partner with HEOR and medical teams to inform value evidence and access strategy ahead of potential launches, consistent with approved materials and internal review processes.
• Provide strategic input on contracting considerations, distribution networks, coverage considerations, and pharmacy-benefit dynamics.
• Analyze policy trends, competitive intelligence, and legislative developments that affect rare disease access; translate insights into strategy.

• Build and maintain compliant, professional relationships with pharmacy directors, medical directors, policy leaders, and other payer stakeholders involved in evidence review and access decision-making.
• Support compliant executive-level discussions regarding coverage policy considerations, prior authorization concepts, utilization management frameworks, and formulary review processes.
• Develop customized, data-driven account plans aligned with Amylyx access objectives.
• Deliver approved clinical, economic, and real-world evidence presentations, as appropriate.

• Develop payer coverage and utilization-management strategy recommendations that support compliant pre- and post-launch access planning.
• Develop and deliver compliant, approved payer-facing resources to support evidence-based payer review processes.

• Engage with payers, as appropriate, to understand evidence expectations, anticipate potential access…